Chu, C., & Hocher, B. (2019). The SGLT2 inhibitor empagliflozin might be a new approach for the prevention of acute kidney injury. Kidney & blood pressure research, 44(2), . https://doi.org/10.1159/000498963
Chicago Style (17th ed.) CitationChu, Chang, and Berthold Hocher. "The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury." Kidney & Blood Pressure Research 44, no. 2 (2019). https://doi.org/10.1159/000498963.
MLA (9th ed.) CitationChu, Chang, and Berthold Hocher. "The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury." Kidney & Blood Pressure Research, vol. 44, no. 2, 2019, https://doi.org/10.1159/000498963.
Warning: These citations may not always be 100% accurate.